Zumutor Biologics, a cancer immunotherapy startup headquartered in the US with R&D in Bengaluru, has raised $7.3 million in its latest funding round. The capital will support ongoing Phase 1 clinical trials of its novel natural killer cell checkpoint therapy and initiate further global studies, including in India.
- Raised $7.3M Series B led by Accel, Bharat Innovation Fund, Premji Invest
- Funds to complete Phase 1 and launch Phase 1B/Phase 2 global studies
- Focused on NK cell checkpoint immunotherapy for solid tumors
What happened
Zumutor Biologics has closed a $7.3 million Series B funding round, led by returning investors Accel and Bharat Innovation Fund, alongside new backers including Premji Invest and notable angel investors. This infusion comes as a strategic step to accelerate the clinical advancement of its cancer immunotherapy candidate, ZM008.
The company plans to utilize the funds to complete its US FDA Phase 1 trials evaluating ZM008 as a stand-alone and combination therapy. Additionally, the capital will support the launch of Phase 1B expansion cohorts and initiate pivotal Phase 2 clinical trials globally, with studies also planned in India where Zumutor maintains an R&D presence.
Why it matters
ZM008 represents a first-in-class natural killer cell checkpoint inhibitor, designed to harness innate immunity to target solid tumors, a challenging area for immunotherapies. Early clinical data indicate promising differentiation in this novel approach, potentially addressing treatment-resistant cancers and improving patient outcomes.
This funding round not only bolsters Zumutor's development pipeline but also underscores investor confidence in India's expanding biotech sector. Government initiatives such as the Biopharma SHAKTI scheme and BIRAC SEED funding are creating a conducive environment for startups to innovate and scale, positioning India as a key player in the global bioeconomy.
What to watch next
The progression of ZM008 through expanded Phase 1 cohorts and into global Phase 2 trials will be critical to validating its clinical potential and safety profile, with results expected to influence subsequent funding and partnership opportunities.
At a broader level, the impact of government policies and investor interest in local biotech innovations will be pivotal for companies like Zumutor aiming to rival global players. Monitoring regulatory milestones and emerging collaborations within India’s bio-sector will provide insight into the market trajectory for advanced cancer immunotherapies.